No abstract available
Keywords:
CALR; JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; ruxolitinib.
Publication types
-
Clinical Trial, Phase III
-
Letter
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Calreticulin / genetics*
-
Humans
-
Nitriles
-
Primary Myelofibrosis / drug therapy*
-
Primary Myelofibrosis / genetics
-
Primary Myelofibrosis / mortality
-
Pyrazoles / administration & dosage*
-
Pyrimidines
-
Retrospective Studies
-
Splenomegaly / drug therapy
-
Survival Rate
-
Thrombocytosis / drug therapy
-
Treatment Outcome
Substances
-
Calreticulin
-
Nitriles
-
Pyrazoles
-
Pyrimidines
-
ruxolitinib